Mortality at 1 Year With Combination Platelet Glycoprotein IIb/IIIa Inhibition and Reduced-Dose Fibrinolytic Therapy vs Conventional Fibrinolytic Therapy for Acute Myocardial Infarction. GUSTO V Randomized Trial - GUSTO V One Year Follow-up


The goal of this study was to assess the safety and efficacy of combination reperfusion therapy with a platelet glycoprotein IIb/IIIa receptor inhibitor (abciximab) and a half dose of a plasminogen activator (reteplase) in reduction of the risk of 1-year death in patients with acute ST elevation myocardial infarction